ViaCell falls on Phase I suspension

Cord blood company VIAC fell $1.39 (22%) to $5.05 on Monday on 2.6 million shares after it suspended enrollment in a Phase I trial of CB001 for use in hematopoietic stem cell transplantation to treat ...